Since formation in April 2020, the impact of the COG-UK consortium has extended to academic research, clinical medicine, public health decisions and government policy.
Enabling the generation of over 1.5 million publicly available viral genomes for use by public health agencies to identify and monitor variants of concern and to track the introduction and spread of COVID-19
Linking over 13,000 host and viral genomes to improve understanding of individual susceptibility to life-threatening COVID-19
Supporting the creation of a national pathogen sequencing service by the public health agencies to embed genomics in the NHS
Furthering the understanding of viral transmission, mutations and variants to guide the development of therapeutics, vaccines and diagnostics
Enhancing sequencing efficiency and lowering cost to make genome sequencing more accessible in low resource settings and to enable faster turnaround times for all
Developing freely available data analysis and interpretation tools for use worldwide
Authoring over 70 publications and preprints to share methods, results and analyses
Funding 14 Principal Investigator research projects on pathogen genomics to advance SARS-CoV-2 science
Forming external collaborations and supporting national studies to integrate pathogen genomics into the UK research landscape
Establishing the COG-Train programme in global viral genomics to support other countries in SARS-CoV-2 sequencing and analysis
Forming Women in COG to promote diversity, equality and inclusion
Hosting 3 Science Showcase events and twelve Internal Seminars, and writing over thirty technical briefings and fifty blog posts to share our findings with all
